AIP
GLUE icon

Ameritas Investment Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Ameritas Investment Partners’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163K Buy
6,720
+1,768
+36% +$33.4K ﹤0.01% 1532
2026
Q1 		$81.5K Buy
4,952
+768
+18% +$14.7K ﹤0.01% 1809
2025
Q4 		$65.6K Hold
4,184
– – ﹤0.01% 1944
2025
Q3 		$31K Hold
4,184
– – ﹤0.01% 2465
2025
Q2 		$18.9K Hold
4,184
– – ﹤0.01% 2691
2025
Q1 		$19.4K Hold
4,184
– – ﹤0.01% 2570
2024
Q4 		$29K Hold
4,184
– – ﹤0.01% 2472
2024
Q3 		$22.2K Buy
4,184
+1,943
+87% +$9.81K ﹤0.01% 2597
2024
Q2 		$8.38K Hold
2,241
– – ﹤0.01% 2974
2024
Q1 		$15.8K Hold
2,241
– – ﹤0.01% 2661
2023
Q4 		$12.7K Hold
2,241
– – ﹤0.01% 2766
2023
Q3 		$10.7K Hold
2,241
– – ﹤0.01% 2817
2023
Q2 		$15.4K Hold
2,241
– – ﹤0.01% 2703
2023
Q1 		$17.5K Hold
2,241
– – ﹤0.01% 2521
2022
Q4 		$16K Hold
2,241
– – ﹤0.01% 2650
2022
Q3 		$18K Hold
2,241
– – ﹤0.01% 2568
2022
Q2 		$21K Hold
2,241
– – ﹤0.01% 2527
2022
Q1 		$31K Buy
2,241
+1,354
+153% +$18.8K ﹤0.01% 2340
2021
Q4 		$18K Hold
887
– – ﹤0.01% 2686
2021
Q3 		$20K Buy
+887
New +$25.4K ﹤0.01% 2696

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameritas Investment Partners's GLUE Position: Q2 2026 in Review

Ameritas Investment Partners increased its Monte Rosa Therapeutics (GLUE) stake by 36% in Q2 2026, buying an estimated $33.4K and bringing the position to 6,720 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #1532.

Ameritas Investment Partners first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Ameritas Investment Partners held 6,720 shares of Monte Rosa Therapeutics worth $163K as of Q2 2026.
  • Ameritas Investment Partners bought 1,768 Monte Rosa Therapeutics shares in Q2 2026, an estimated $33.4K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1532 holding.
  • Ameritas Investment Partners first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.